Antonelli G, Dianzani F
Department of Biomedicine, University of Pisa, Italy.
Arch Virol Suppl. 1993;8:271-7. doi: 10.1007/978-3-7091-9312-9_28.
A massive amount of information on interferons (IFNs) has been gathered since their original description as antiviral agents in 1957. Human IFNs have now been used clinically for over a decade and their therapeutic efficacy has been well established for some human neoplasias and viral diseases. During these studies, it has also been documented that some of the patients treated with IFNs can develop antibodies to IFNs which can affect their therapeutic efficacy. Here, it is summarized what is currently known on the biological and clinical aspects of these antibodies.
自1957年干扰素最初被描述为抗病毒剂以来，人们已经收集了大量关于干扰素（IFN）的信息。人类干扰素现已在临床上使用了十多年，其治疗效果在一些人类肿瘤和病毒性疾病中已得到充分证实。在这些研究中，也有记录表明，一些接受干扰素治疗的患者会产生针对干扰素的抗体，这些抗体可能会影响其治疗效果。在此，总结一下目前关于这些抗体的生物学和临床方面的已知情况。
